Stryker Corporation 10-Q Summary: Period Ended September 30, 2005
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2005, and the nine-month period ended on that date. Stryker Corporation is a leading medical device company operating in two primary segments: Orthopaedic Implants and MedSurg Equipment. The company markets products to over 6,000 hospitals and healthcare facilities in more than 100 countries. Domestic sales accounted for approximately 65% of total revenues for the nine-month period, with international sales comprising the remaining 35%.
Key Financial Metrics
| Metric (in millions) | Q3 2005 | Q3 2004 | 9 Months 2005 | 9 Months 2004 |
|---|---|---|---|---|
| Net Sales | $1,171.9 | $1,028.7 | $3,593.0 | $3,106.8 |
| Gross Profit | $756.4 | $663.6 | $2,326.2 | $2,008.8 |
| Operating Income | $232.4 | $74.3 | $740.2 | $487.6 |
| Net Earnings | $132.1 | $14.4 | $489.5 | $303.0 |
| Diluted EPS | $0.32 | $0.04 | $1.19 | $0.74 |
| Cash from Operations | $263.0 | $186.1 | $482.2 | $288.7 |
| Cash & Equivalents | $200.4 | - | - | - |
| Marketable Securities | $332.2 | - | - | - |
| Total Debt (Current + Long-Term) | $9.0 | - | - | - |
Note: Q3 2004 results were significantly impacted by a $120.8 million non-cash charge for purchased in-process research and development related to the SpineCore acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% in Q3 2005 and 16% for the nine-month period compared to 2004. Growth was driven by increased unit volume, favorable product mix, and acquisitions (eTrauma in Q1 2005). Foreign currency exchange rates provided a favorable impact of approximately $4.1 million in Q3 and $38.8 million for the nine months.
- Profitability: Operating income surged 213% in Q3 2005 compared to Q3 2004, primarily due to the absence of the $120.8 million SpineCore write-off recorded in the prior year. Gross margins remained stable at approximately 64.5% for the quarter and 64.7% for the nine months.
- Tax Impact: The effective income tax rate for Q3 2005 was 43.0%, compared to 80.1% in Q3 2004. The 2005 rate includes a $31.3 million charge for the repatriation of foreign earnings under the American Jobs Creation Act. Excluding this charge and the 2004 SpineCore write-off, the effective tax rate was 29.5% for both periods.
- Acquisitions: In Q1 2005, Stryker acquired eTrauma.com Corp. for approximately $50 million to expand its MedSurg Equipment segment. In Q3 2004, the company acquired SpineCore, Inc., resulting in a significant one-time charge.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects diluted net earnings per share to approximate $1.75 for the full year 2005. Net sales are expected to increase 14% to 15%, driven by Orthopaedic Implants and MedSurg Equipment growth. Excluding foreign currency effects, sales growth is expected to be 14%.
- 2006 Outlook: The company anticipates diluted net earnings per share of approximately $2.10 for 2006, excluding the impact of new stock-based compensation accounting rules.
- Capital Allocation: The Board approved a plan to repatriate approximately $722 million of foreign earnings in Q4 2005. This will be funded by existing cash, marketable securities, and approximately $200 million in third-party borrowings.
- Risks and Contingencies:
- Legal Investigations: The company is cooperating with Department of Justice investigations regarding billing practices of its Physiotherapy Associates subsidiary and consulting contracts with orthopedic surgeons.
- Accounting Changes: Stryker plans to adopt FASB Statement No. 123(R) effective January 1, 2006, which will require recognizing stock-based compensation expense. Pro forma results suggest this would reduce Q3 2005 diluted EPS by $0.03.
- Market Risks: Potential pricing pressure in the U.S., Japan, and other markets; regulatory actions; and foreign exchange fluctuations.
Investor Verification Checklist
- Repatriation Impact: Verify the execution of the $722 million foreign earnings repatriation in Q4 2005 and the associated $31.3 million tax charge.
- Adjusted Earnings: Review non-GAAP adjusted earnings ($163.4 million for Q3 2005) to understand organic performance excluding the 2004 SpineCore charge and 2005 repatriation tax.
- Stock-Based Compensation: Monitor the impact of the January 1, 2006 adoption of FASB 123(R) on future net earnings and EPS.
- Legal Proceedings: Track the status of the DOJ investigations into Physiotherapy Associates and surgeon consulting agreements.
- Debt Levels: Confirm the drawdown of the anticipated $200 million borrowing for repatriation and the subsequent paydown schedule in 2006.